In addition, recent preclinical studies have shown that dual inhibition of mTOR with rapamycin and Akt with perifosine prevents mTOR inhibition-initiated Akt activation and significantly enhances antitumor effects in lung cancer [50] and multiple myeloma [51]. The gene discussed is MTOR; the disease is plasma cell myeloma.